NCT02879578View on ClinicalTrials.gov

Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

July 25, 2016

Primary Completion Date

November 1, 2017

Study Completion Date

November 1, 2017

Conditions
Tourette Syndrome
Interventions
DRUG

Valbenazine

Trial Locations (13)

Unknown

Sun City

San Diego

Loxahatchee Groves

St. Petersburg

Tampa

Naperville

Lincoln

Summit

New York

Norristown

Nashville

Fort Worth

Spokane

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY